Health Care [ 9/12 ] | Biotechnology [ 35/76 ]
NASDAQ | Common Stock
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States.
Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.
The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016.
BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 14, 24 | -0.22 Increased by +48.84% | -0.33 Increased by +33.33% |
| Feb 13, 24 | -0.22 Increased by +56.00% | -0.32 Increased by +31.25% |
| Nov 8, 23 | -0.29 Increased by +23.68% | -0.31 Increased by +6.45% |
| Aug 16, 23 | -0.25 Increased by +24.24% | -0.40 Increased by +37.50% |
| May 12, 23 | -0.43 Decreased by -53.57% | -0.35 Decreased by -22.86% |
| Feb 10, 23 | -0.50 Decreased by -78.57% | -0.25 Decreased by -100.00% |
| Nov 4, 22 | -0.38 Decreased by -65.22% | -0.28 Decreased by -35.71% |
| Sep 27, 22 | -0.33 Increased by +96.76% | -0.37 Increased by +10.81% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | N/A Decreased by N/A% | -4.94 M Increased by +45.78% | - - |
| Mar 31, 24 | 0.00 Decreased by N/A% | -8.95 M Increased by +41.19% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -8.40 M Increased by +55.57% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -10.71 M Increased by +2.47% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -9.11 M Decreased by -52.63% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -15.23 M Decreased by -104.99% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -18.91 M Decreased by -249.24% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by N/A% | -10.98 M Decreased by -98.21% | Decreased by N/A% Decreased by N/A% |